Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

BACKGROUND: We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadgeel, Shirish, Shaw, Alice T, Barlesi, Fabrice, Crinò, Lucio, Yang, James Chih-Hsin, Dingemans, Anne-Marie C, Kim, Dong-Wan, de Marinis, Filippo, Schulz, Mathias, Liu, Shiyao, Gupta, Ravindra, Kotb, Ahmed, Ou, Sai-Hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765233/
https://www.ncbi.nlm.nih.gov/pubmed/29149104
http://dx.doi.org/10.1038/bjc.2017.395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765233/
https://www.ncbi.nlm.nih.gov/pubmed/29149104
http://dx.doi.org/10.1038/bjc.2017.395

Ejemplares similares